Inhibitors of spinster homolog 2 (SPNS2) for use in therapy

A compound according to Formula IA:

• wherein
• X is a C6-C10-aryl or 5- to 10-membered heteroaryl (wherein 1 to 4 heteroaryl ring members are independently selected from N, O, and S);
• R1 and R2 are independently selected from the group consisting of H, C1-C6-alkyl, C1-C6-alkoxy, C1-C6-haloalkoxy, C3-C8-cycloalkyl, C1-C6-haloalkyl, CN, and halo;
• W is a bond, O, NH, —NHC(O)—, or —O—(N═)C(R)— (wherein R is H or C1-C6-alkyl);
• V is selected from the group consisting of C1-C14-alkyl, C2-C12-alkenyl, (C6-C10)aryl, (C6-C10)heteroaryl, —C1-C10-alkyl-(C6-C10)aryl, —C2-C12-alkenyl-(C6-C10)aryl, —C1-C10-alkyl-(C3-C8)cycloalkyl, -(3- to 14-membered heterocycloalkyl) (wherein 1-4 heterocycloalkyl members are independently selected from N, O, and S), —(C1-C10)alkyl-(3- to 14-membered heterocycloalkyl) (wherein 1-4 heterocycloalkyl members are independently selected from N, O, and S);
• T is selected from the group consisting of a bond, —C(O)—, —C(O)NRx—, —C(S)NRx—, —NRxC(O)—, —NRx—, —NRxC(O)NRx—, and —NRxC(O)O—;
• Rx in each instance is independently selected from H and C1-C6-alkyl;
• m is an integer selected from 0, 1, 2, 3, 4, 5, and 6;
• n is an integer selected from 1 and 2, wherein the sum of n and o is greater than 0;
• each “---” is a single bond that is optionally present, wherein all “---” are simultaneously present or absent, and wherein
• when “---” is present, then
• o is selected from 1, 2, and 3;
• and
• p is 0, (N)pR6 represents a bond, and U is —CH— or N, or
• p is 1 and U is —CH—;
• and
• when “---” is not present, then o is 0 and U is —CH2— or NH;
• q is an integer selected from 1, 2, and 3;
• R3 is selected from the group consisting of, H, C1-C6-alkyl, and —C(NH)NH2;
• R4 is absent when “---” is present, and when “---” is absent, then R4 is H or C1-C6-alkyl;
• each R5 is independently selected from the group consisting of H, C1-C6-alkyl, C1-C6-alkoxy, C1-C6-haloalkoxy, C3-C8-cycloalkyl, C1-C6-haloalkyl, CN, NH2, and halo;
• R6 is H or C1-C6-alkyl;
• wherein each alkyl, alkoxy, alkenyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl, and heteroaryl is optionally substituted with 1-5 substituents independently selected from the group consisting of hydroxy, halo, C1-C6-haloalkoxy, C1-C6-haloalkyl, —NR′2, —NHC(O)(OC1-C6-alkyl), —NO2, —CN, oxo, —C(O)OH, —C(O)O(C1-C6-alkyl), —C1-C6-alkyl(C1-C6-alkoxy), —C(O)NH2, C1-C6-alkyl, —C(O)C1-C6-alkyl, —OC1-C6-alkyl, —Si(C1-C6-alkyl)3, —S(O)0-2—(C1-C6-alkyl), C6-C10-aryl, —(C1-C6-alkyl)(C6-C10-aryl), 3- to 14-membered heterocycloalkyl, and —(C1-C6-alkyl)-(3- to 14-membered heterocycle) (wherein 1-4 heterocycle members are independently selected from N, O, and S), and —O(C6-C14-aryl);
• and
• wherein each R′ is independently selected from the group consisting of C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C6-C10-aryl, 3- to 14-membered heterocycloalkyl and —(C1-C6-alkyl)-(3- to 14-membered heterocycloalkyl) (wherein 1-4 ring members are independently selected from N, O, and S), and 5- to 10-membered heteroaryl (wherein 1-4 heteroaryl members are independently selected from N, O, and S;
• or a pharmaceutically acceptable salt thereof.